Acute Promyelocytic Leukemia Global Clinical Trials Review, H1, 2017

GlobalData
116 Pages - GLDATA60413
$2,500.00

Summary

GlobalData's clinical trial report, “Acute Promyelocytic Leukemia Global Clinical Trials Review, H1, 2017" provides an overview of Acute Promyelocytic Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Promyelocytic Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Teva Pharmaceutical Industries Ltd
Pfizer Inc
CytRx Corp
Seattle Genetics Inc
Zenith Technology Corporation Ltd
Syndax Pharmaceuticals Inc
Sanofi
Douglas Pharmaceuticals Ltd
Bayer AG
AbbVie Inc

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Acute Promyelocytic Leukemia to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Acute Promyelocytic Leukemia to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Acute Promyelocytic Leukemia Therapeutics Clinical Trials 28
Prominent Drugs 30
Latest Clinical Trials News on Acute Promyelocytic Leukemia 31
Nov 30, 2016: Teva to Present Data on TRISENOX (arsenic trioxide) Injection at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition 31
Clinical Trial Profile Snapshots 32
Appendix 111
Abbreviations 111
Definitions 111
Research Methodology 113
Secondary Research 114
About GlobalData 115
Contact Us 115
Disclaimer 115
Source 116

List of Tables
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials by Region, 2017* 5
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 9
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 13
Proportion of Acute Promyelocytic Leukemia to Oncology Clinical Trials, G7 Countries (%), 2017* 14
Acute Promyelocytic Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
Acute Promyelocytic Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
Proportion of Acute Promyelocytic Leukemia to Oncology Clinical Trials, E7 Countries (%), 2017* 17
Acute Promyelocytic Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
Acute Promyelocytic Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials by Phase, 2017* 20
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 21
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
Acute Promyelocytic Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 25
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2017* 5
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 6
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 9
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 10
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 11
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 12
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 13
Proportion of Acute Promyelocytic Leukemia to Oncology Clinical Trials, G7 Countries (%), 2017* 14
Acute Promyelocytic Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
Acute Promyelocytic Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
Proportion of Acute Promyelocytic Leukemia to Oncology Clinical Trials, E7 Countries (%), 2017* 17
Acute Promyelocytic Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
Acute Promyelocytic Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 20
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 21
Acute Promyelocytic Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
Acute Promyelocytic Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 25
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
Acute Promyelocytic Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
GlobalData Methodology 112

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports